simmitecan
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT01832298)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CCc1c(OC(=O)N2CCC(N3CCCCC3)CC2)ccc2nc3c(cc12)Cn1c-3cc2c(c1=O)COC(=O)[C@]2(O)CC.Cl- Mol. weight
- 635.16 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4301491 ↗
- ChEMBLCHEMBL4297325 ↗
Also known as
- 9-allyl-10-piperidyl piperidine formyloxy-camptothecin
- simmitecan
- simmitecan
- simmitecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02870036 | Phase 1 | Oct 1, 2016 | Chinese Academy of Medical Sciences, ShangHai HaiHe Pharmaceutical |
| NCT01832298 | Phase 1 | Dec 1, 2012 | Chinese Academy of Medical Sciences, Harbin Medical University, ShangHai HaiHe Pharmaceutical, Sichuan University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2012 |
| ShangHai HaiHe Pharmaceutical | For profit | 2 | 2 | 1 | 2012 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1